Boston Scientific Announces Strategic Investment in MiRus LLC

Boston Scientific Corporation has invested $1.5 billion for a 34% equity stake in MiRus LLC, a company developing advanced biomaterials and implants, including the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement system. Along with the investment, Boston Scientific has secured an exclusive option to acquire the TAVR system upon meeting certain milestones. The SIEGEL valve, made from a proprietary rhenium alloy, aims to improve outcomes for patients with aortic stenosis. This investment is expected to have minimal impact on Boston Scientific’s adjusted earnings per share in 2026.